BioMarin Pharmaceutical Inc.

BMRN Healthcare Biotechnology

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

54.68 1.37 −2.44%
Market cap
$10.9B
P/E
144×
Fwd P/E
16.1×
Dividend yield
—
F-score
5/9
Altman Z
5.67
Beneish M
−2.49
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
32.65 29.21 110.17 130.66 0.00 18.58 0.00 0.00 0.00 0.00
Piotroski F-Score
5 8 6 8 4 4 6 6 4 4
P/S ratio
3.54 4.38 7.61 8.89 8.75 8.52 8.88 10.11 12.09 12.76
Altman Z-Score
5.67 6.68 6.38 7.14 5.96 5.93 5.83 6.32 5.25 5.94
P/FCF ratio
15.90 25.73 356.59 126.21 87.18 1,056.63 0.00 298.03 697.39 0.00
Altman Z″-Score (non-manufacturers)
7.43 7.30 4.34 4.72 3.87 4.02 2.16 2.97 2.41 1.34
Beneish M-Score
(2.49) (2.44) (2.14) (2.33) (2.93) (1.55) (2.39) (2.26) (2.58) (2.74)
P/Operating CF
114.39 67.29 670.13 2,746.77 1,444.99 (1,184.60) 263.99 305.36 1,086.50 (67,848.34)
P/B ratio
1.87 2.21 3.72 4.05 3.79 3.86 4.85 5.08 5.65 5.15
Price to Tangible BV
2.01 2.40 4.13 4.58 4.39 4.54 6.13 6.62 7.58 7.07
EV/Sales
3.39 4.36 7.62 8.80 8.79 8.53 8.94 10.19 11.92 12.66
EV/EBITDA
22.57 21.74 65.60 69.33 526.05 254.84 5,358.31 0.00 205.36 0.00
EV/Operating CF
13.20 21.72 115.73 104.84 53.29 185.98 315.61 752.03 (1,787.89) (62.07)
EV/FCF
15.24 25.63 356.84 124.87 87.58 1,058.08 (168.97) 300.41 687.66 (40.24)
Quick Ratio
3.25 2.96 1.45 2.98 2.54 3.07 1.21 2.73 2.03 2.29
Current Ratio
5.21 5.33 2.51 4.67 4.16 4.76 2.08 3.93 2.70 3.24
Net Debt/EBITDA
(1.99) (0.95) 0.05 (0.75) 2.44 0.35 33.17 9.23 (2.91) 0.15
Debt/Assets
7.86% 8.52% 15.89% 17.15% 18.14% 18.59% 18.08% 18.76% 25.35% 16.98%
Debt/Equity
0.10 0.11 0.22 0.24 0.26 0.26 0.27 0.28 0.42 0.25
Asset Turnover
0.44 0.41 0.37 0.34 0.31 0.35 0.37 0.33 0.30 0.29
Operating CF/Net income
2.37 1.34 0.95 1.24 (4.75) 0.10 (2.02) (0.26) 0.07 0.36
Capex/Depreciation
(1.48) (0.99) (1.13) (0.27) (1.05) (0.67) (1.34) (0.99) (0.82) (1.51)
Interest Coverage
37.57 38.23 10.72 10.08 (5.37) (1.48) (4.28) (2.83) (0.34) (20.34)
ROE
5.94% 8.05% 3.51% 3.19% (1.53%) 23.63% (0.78%) (2.67%) (4.20%) (24.39%)
ROA
4.79% 6.17% 2.54% 2.29% (1.08%) 16.21% (0.52%) (1.70%) (2.70%) (16.26%)
ROIC
5.00% 5.92% 2.34% 2.28% (1.19%) (0.66%) (1.95%) (2.84%) (0.36%) (18.88%)
Return on Tangible Assets
8.41% 11.64% 5.89% 4.37% (2.32%) 29.63% (1.18%) (3.11%) (5.12%) (35.38%)
Average Days of Receivables
102.91 84.48 95.61 80.33 73.82 87.96 80.84 83.87 72.62 70.36
Research and Development Expense of Revenue
28.62% 26.18% 30.87% 30.99% 34.06% 33.76% 41.96% 46.70% 46.49% 59.27%
Selling, General and Administrative Expense of Revenue
35.79% 35.36% 36.89% 39.28% 41.13% 39.65% 39.96% 40.53% 42.20% 42.67%
Intangible Assets out of Total Assets
0.05 0.06 0.07 0.08 0.10 0.10 0.14 0.16 0.15 0.19
Share Based Compensation of Revenue
5.63% 7.06% 8.56% 9.37% 10.68% 10.20% 9.38% 9.98% 10.68% 12.06%
Graham Net Nets
0.21 0.15 0.06 0.05 0.03 0.04 0.02 0.04 0.02 0.01
Graham Number
36.05 38.82 22.98 20.75 0.00 49.11 0.00 0.00 0.00 0.00
Earnings Yield
3.06% 3.42% 0.91% 0.77% (0.40%) 5.38% (0.17%) (0.50%) (0.73%) (4.58%)
Free Cash Flow Yield
6.29% 3.89% 0.28% 0.79% 1.15% 0.09% (0.60%) 0.34% 0.14% (2.47%)
Revenue per Share
16.80 15.02 12.88 11.31 10.10 10.29 9.52 8.42 7.53 6.73
Operating CF per Share
4.32 3.01 0.85 0.95 1.67 0.47 0.27 0.11 (0.05) (1.37)
Capex per Share
(0.58) (0.46) (0.57) (0.15) (0.65) (0.39) (0.77) (0.53) (0.43) (0.89)
Free Cash Flow per Share
3.74 2.55 0.28 0.80 1.01 0.08 (0.50) (0.42) (0.48) (2.27)
Cash per Share
8.14 5.99 5.72 6.97 5.54 5.89 4.21 6.12 8.00 4.76
Shareholders Equity per Share
31.74 29.77 26.36 24.85 23.33 22.71 17.44 16.76 16.10 16.67
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
31.74 29.77 26.36 24.85 23.33 22.71 17.44 16.76 16.10 16.67
Free Cash Flow
717.02 485.42 51.65 147.69 185.31 15.01 (90.14) (74.41) (82.98) (376.22)
Working Capital
3,194.46 2,625.44 1,779.06 2,162.57 1,727.89 1,849.67 1,009.64 1,532.97 1,390.63 982.48
Capital Expenditures
(110.97) (87.42) (107.61) (28.21) (119.22) (70.36) (138.41) (94.62) (74.22) (148.38)
Net Current Asset Value
2,446.47 1,901.48 1,066.03 979.54 535.28 600.20 374.49 597.03 382.68 164.38
EV/EBIT
26.69 25.70 99.21 114.56 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.03 0.03 0.04 0.01 0.06 0.04 0.08 0.06 0.06 0.13
Price to Operating Income
27.84 25.80 99.14 115.79 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.08 0.08 0.09 0.10 0.11 0.10 0.10 0.10 0.10 0.12
Cash ROIC
8.70% 6.57% 0.73% 2.11% 2.91% 0.24% (1.91%) (1.52%) (1.54%) (8.87%)
Accounts Receivable Turnover
4.11 4.41 4.42 5.02 4.49 4.51 4.73 4.94 5.51 5.87
Accounts Payable Turnover
1.05 0.90 0.85 0.94 0.95 0.99 0.71 0.75 0.63 0.55
Inventory Turnover
0.57 0.50 0.53 0.60 0.64 0.76 0.59 0.63 0.58 0.67
Average Days of Payables
386.16 381.83 468.65 415.75 386.53 342.91 579.41 506.28 606.74 645.14
Days of Inventory on Hand
660.81 775.41 759.54 648.76 602.50 486.33 690.75 614.62 718.23 618.36
Average Receivables
784.37 647.12 547.51 417.36 410.88 412.88 360.02 302.00 238.32 190.12
Average Payables
683.01 645.07 628.05 535.61 495.41 531.58 503.96 419.61 386.21 381.51
Average Inventory
1,265.77 1,169.92 1,000.63 835.38 737.61 689.41 605.57 503.32 415.45 313.40
Average Assets
7,291.48 6,915.27 6,608.34 6,189.92 5,926.40 5,269.03 4,558.58 4,530.13 4,328.41 3,876.53
Average Common Equity
5,872.49 5,304.77 4,777.35 4,434.41 4,185.84 3,614.19 3,045.16 2,888.30 2,787.47 2,583.56

Fold the line items

Columns are period end dates